Skip to main content
Download PDF

Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response

Journal of Hematology & Oncology volume 13, Article number: 158 (2020) Cite this article

Abstract

Background

Chemoresistance remains a major treatment obstacle in multiple myeloma (MM). Novel new therapies are thus in need. Transient Receptor Potential Vanilloid type 1 (TRPV1) is a calcium-permeable ion channel that has been demonstrated to be expressed in solid tumors. Calcium channels have been shown to be involved in the regulation of cell proliferation, chemoresistance, migration and invasion. The aim of the current study was to evaluate its possible role in MM.

Methods

Pharmacological inhibitor was used to evaluate the role of TRPV1 in MM cell lines and primary MM cells. Flow cytometry, molecular analysis, fluorescent microscopy, proteomic analysis and xenograft in vivo model of MM with BM involvement were employed to assess the effect of TRPV1 inhibition and decipher its unique mechanism of action in MM.

Results

TRPV1 was found to be expressed by MM cell lines and primary MM cells. TRPV1 inhibition using the antagonist AMG9810-induced MM cell apoptosis and synergized with bortezomib, overcoming both CXCR4-dependent stroma-mediated and acquired resistance. In accordance, AMG9810 suppressed the expression and activation of CXCR4 in MM cells. TRPV1 inhibition increased mitochondrial calcium levels with subsequent mitochondrial ROS accumulation and depolarization. These effects were reversed by calcium chelation, suggesting the role of calcium perturbations in oxidative stress and mitochondrial destabilization. Furthermore, AMG9810 abolished bortezomib-induced accumulation of mitochondrial HSP70 and suppressed protective mitochondrial unfolded protein response. Proteomics revealed unique molecular signature related to the modification of ubiquitin signaling pathway. Consequently, 38 proteins related to the ubiquitylation machinery were downregulated upon combined bortezomib/AMG9810 treatment. Concomitantly, AMG9810 abolished bortezomib-induced ubiquitination of cytosolic and mitochondrial proteins. Furthermore, bortezomib/AMG9810 treatment induced mitochondrial accumulation of PINK1, significantly reduced the mitochondrial mass and promoted mitochondrial-lysosomal fusion, indicating massive mitophagy. Finally, in a recently developed xenograft model of systemic MM with BM involvement, bortezomib/AMG9810 treatment effectively reduced tumor burden in the BM of MM-bearing mice.

Conclusions

Altogether, our results unravel the mechanism mediating the strong synergistic anti-MM activity of bortezomib in combination with TRPV1 inhibition which may be translated into the clinic.

Introduction

Multiple myeloma (MM) is a neoplastic disorder that is characterized by clonal proliferation of plasma cells in the bone marrow (BM). It accounts for 10% of all hematological malignancies [1, 2]. Development of novel pharmaceutical agents has resulted in major advances in the treatment of MM in the last two decades [3]. Treatment strategies with that combined immune-modulatory drugs, proteasome inhibitors, conventional chemotherapy and monoclonal antibodies resulted in substantial progression in treatment outcome. However, despite improvements in patient survival rates, MM remains an incurable disease. Acquired or de novo resistance to current anti-MM therapy remains a major treatment obstacle [4, 5]. Novel new therapies are thus in need.

The transient receptor potential (TRP) channel superfamily is one of the largest families of cation channels [6]. Transient Receptor Potential Vanilloid type 1 (TRPV1) was the first identified and is the most extensively studied member of the vanilloid receptor subfamily of TRP ion channels. The TRPV1 receptor is a non-selective cation channel with a preference for calcium transmission and was initially identified as a specific receptor for capsaicin that causes a burning sensation [7]. Further studies revealed that TRPV1 is a polymodal receptor and is sensitive to multiple external stimuli that include capsaicin, ethanol, temperature above 43 °C and acid/basic pH changes [8, 9]. TRPV1 channel is involved in the regulation of calcium signaling, crucial for many cellular processes including proliferation, apoptosis, secretion of cytokines or T cell activation [10, 11]. Its broad expression in a wide range of tissues such as skin, respiratory airways, gastrointestinal tract, urinary epithelial cells, pancreatic B cells and he immune system, underlines the important role of TRPV1 [12,13,14,15,16,17]. Currently, TRPV1 was shown to be implicated in neurogenic inflammation, neuropathic pain, autoimmune disorders, immune cells functioning and cancer [11]. Functional expression of TRPV1 was demonstrated in several human malignancies including breast, prostate, urothelial cancer and glioma [18,19,20,21,22].

The role of TRPV1 channel in MM tumor progression and drug resistance has not been studied. We, therefore, evaluated the role of TRPV1 channel in MM, demonstrating that TRPV1 is expressed in MM cell lines and primary MM cells. TRPV1 inhibition using pharmacological blocker AMG9810 promotes MM cell death and synergizes with anti-MM agent bortezomib. Furthermore, our results reveal the mechanism that underlies the synergism between bortezomib and AMG9810, demonstrating that TRPV1 inhibition disturbs mitochondrial calcium signaling, suppresses bortezomib-induced mitochondrial unfolded protein response (mtUPR) and promotes mitophagy. Altogether, simultaneous TRPV1 and proteasome targeting appears to be promising novel therapeutic strategy in MM.

Materials and methods

Cell lines and MM patient samples

The following human MM cell lines were obtained from ATCC (Rockville, MD, USA): RPMI8226, U266 and NCI-H929. The CAG MM cell line (generated by the group at the University of Arkansas for Medical Sciences (UAMS) [23]), OPM-1 and OPM-2 (originate from the same individual) were kindly donated by Prof. Israel Vlodavsky, Technion, Israel. Cells were maintained in log-phase growth in RPMI1640 medium (Biological Industries, Israel) supplemented with 10% heat-inactivated fetal calf serum (FCS), 1 mM L-glutamine, 100 U/ml penicillin and 0.01 mg/ml streptomycin (Biological Industries) in a humidified atmosphere of 5% CO2 at 37 °C. MM cell lines were authenticated in 2019 at the Genomics Center of Biomedical Core Facility, Technion, using the Promega GenePrint 24 System. Primary MM cells were isolated from bone marrow aspirates of myeloma patients. The study was approved by Institutional Review Board of the Sheba Medical Center. Mononuclear cells were collected after separation on Ficoll-Paque (Pharmacia Biotech). MM cells were purified (> 95% purity) by CD138+ isolation using MACS magnetic cell sorter (Miltenyi Biotec Inc.).

Preparation of BMSCs and co-culture experiments

Primary human bone marrow stromal cells (BMSCs) were generated from bone marrow aspirates of consenting healthy donor volunteers. BMSCs were isolated by plate adherence and expanded as previously described [24].

Inhibitors

The following chemicals were used: bortezomib, carfilzomib, AMG9810, capsaicin and MLN4924 from Cayman.

Cell line transduction

In order to stably over-express CXCR4, RPMI8226 cells were transduced with the lentiviral bicistronic vector encoding for CXCR4 and GFP genes, as previously described [25]. For CXCR4 silencing, cells with exogenously expressed CXCR4 (RPMI8226-CXCR4) were stably transduced with lentiviral vectors encoding for specific anti-CXCR4 short hairpin RNA (shRNA) (pLKO.1-shRNA-CXCR4 TRCN, Mission TRC Sigma) using the same envelope and packaging constructs.

Analysis of surface markers

Expression levels of CXCR4 were evaluated by immune staining with allophycocyanin (APC)-conjugated anti-CXCR4 monoclonal antibody (12G5 clone) (eBioscience, USA). In primary MM samples, counterstaining with anti-CD138 fluorescein (FITC)-conjugated antibody (IQ products, Netherlands) was performed. The cells were analyzed by Navios (Becton Coulter), using Kaluza software.

XTT viability assay

Cells were exposed in vitro to increasing concentrations of AMG9810 for 48 h, and viability was determined as described in Additional file 1.

Cell cycle analysis

Cells were exposed in vitro to increasing concentrations of AMG9810 and bortezomib for 48 h and analyzed by FACS as described in Additional file 1.

Assessment of apoptosis

Apoptosis was determined as described in Additional file 1.

Quantitative RT-PCR analysis

RNA isolation and qRT-PCR analysis were performed as described in Additional file 1.

Acridine Orange staining

To assess vesicle acidification, MM cells were exposed to AMG9810 (10 µM), bortezomib, capsaicin or their combinations for different time points and were loaded with 1 µg/ml acridine orange (AO) (Sigma), for 30 min in 37 °C, and analyzed by flow cytometry.

Mitochondrial ROS accumulation

Following treatment with indicated reagents, levels of mitochondrial ROS were assessed using MitoSOX Red in combination with Annexin V-CF647 using FlowCellect™ MitoStress Kit (Merck Millipore) according to the manufacturer’s instructions.

Mitochondrial mass detection

Mitochondrial mass in live cells treated with indicated reagents was monitored using the probe MitoSpy™ Red CMXRos (Biolegend) at final concentration of 100 nM, according to the manufacturer’s instructions, and analyzed by flow cytometry.

Assessment of mitochondrial membrane potential (ΔΨm)

Effect of AMG9810 and bortezomib treatment on ΔΨm was evaluated using DiOC6 (Sigma-Aldrich) staining as previously described [24].

Cell migration assay

Migration of MM cell lines in response to various CXCL12 concentrations (5–500 ng/ml) (PeproTech EC) was evaluated using 5-µm pore size transwells (Costar). The quantity of cells migrating within four hours to the lower compartment was determined by FACS and expressed as a percentage of the input. For TRPV1 inhibition, cells were pre-treated (30 min in 37 °C) with AMG9810 (10 µM) and subjected to migration.

Cell adhesion assay

Cell adhesion was determined as described in Additional file 1.

Assessment of lysosomal membrane permeabilization

MM cells were exposed to AMG9810 (5–10 µM), bortezomib (3–5 nM) or their combination for 24 or 48 h, labeled with LysoTracker (Cell Signaling Technology) for 30 min, 37 °C for 30 min, and analyzed by flow cytometry.

Immunofluorescent staining and microscopy

MM cells were exposed to AMG9810 (10 µM), in the absence or presence of BAPTA-AM (5 µM) for 1 h. Next the cells were seeded on poly-D-lysine pre-coated slides for 30 min and loaded with Rhod-2 calcium marker (Invitrogen) for additional 30 min. Next, the cells were fixed with 100% ice-cold methanol for 5 min, washed with PBSx1 and permeabilized with 0.5% saponin for 30 min. After blocking non-specific binding with 1% BSA for 1 h, anti-COX IV antibody (1:500) (Cell Signaling Technology) in 0.5% saponin-containing buffer was applied for 2-h incubation. Thereafter, the slides were washed with PBSx1 and incubated with secondary anti-rabbit (1:500), FITC-conjugated antibody for 1 h and subsequently counterstained with DAPI-containing mounting solution (Vector Laboratories). Stained cells and negative controls were evaluated using an Olympus BX53 microscope connected to an Olympus DP73 camera (Olympus, Melville, NY, USA). Images were captured for analysis using cellSens imaging software (Olympus, Melville, NY, USA).

Mitochondrial calcium and total cellular calcium measurements by flow cytometry

The mitochondrial calcium indicator Rhod-2, AM (Invitrogen), was used to assess mitochondrial calcium in MM cells. To evaluate total intracellular calcium levels, eFluor 514 (eBioscience™) calcium sensor dye was utilized. Cells were pre-treated with indicated treatments and then loaded with 10 μM Rhod-2 or 5 μM eFluor 514 for 30 min, washed with PBSx1 and analyzed by Navios (Beckman Coulter), using Kaluza software.

Immunoblot analysis

Mitochondria/cytosol fractionation was performed using commercial kit (Biovision) according to the manufacturer’s instructions. Total protein lysates (50–70 μg) or mitochondria/cytosol fractions (30 μg) were resolved by electrophoresis in 10% SDS-PAGE and transferred onto PVDF membranes. Blots were subjected to a standard immunodetection procedure using specific antibodies and the ECL substrate (Biological Industries). Signal was detected using a Bio-Rad image analyzer (Bio-Rad). The primary antibodies used were: CHOP, BCL-2, MCL-1, BCL-XL, phospho-Erk1/2, phospho-AKT, phospho-pS6, HSP70, HSP40, COX IV, AIF, PINK1, VDAC, LAMP1, ubiquitin, α-tubulin (Cell Signaling Technology), MCL-1 (Santa-Cruz) and β-actin (Sigma-Aldrich).

Mass spectrometry-based proteomics

RPMI8226 cells were treated with bortezomib (10 nM), AMG9810 (10 µM) or combination of both drugs and subjected to proteomic analysis (Smoler proteomics center, Technion). Briefly, the samples were digested by trypsin and analyzed by LC–MS/MS on Q Exactive plus (Thermo). The data were analyzed with MaxQuant 1.6.0.16 vs the Human Uniprot database. The identifications are filtered for proteins identified with false discovery rate (FDR) < 0.01 with at least 2 peptides in the project.

Murine xenograft models of disseminated human MM and drug treatment

NSG mice were maintained under defined flora conditions at the Hebrew University Pathogen-Free Animal Facility (Jerusalem, Israel). All experiments were approved by the Animal Care Committee of the Hebrew University. Mice were injected intravenously with RPMI8226-CXCR4 human cells (5 × 106/mouse). Endpoints were paraplegia and weight loss > 10%. The mice were killed on the same day the endpoint was reached. Disease was verified by measurement of human immunoglobulin in plasma of inoculated mice using the ELISA kit (Immunology Consultants Laboratory). To investigate the therapeutic potential of AMG9810 as a single agent or in combination with bortezomib, three days after inoculation with RPMI8226-CXCR4 cells, mice were randomized and treated with intraperitoneal (i.p.) injections of either AMG9810 (10 mg/kg) twice per week, subcutaneous injections of bortezomib (0.5 mg/kg) twice per week, or with a combination of both agents, for a total of 6 injections. Animals were killed 24 days after tumor inoculation.

Statistical analyses

Data are expressed as the mean ± standard deviation (SD) or standard error (SE). Statistical comparisons of means were performed by a two-tailed unpaired Student's t test or the Mann–Whitney U test.

Results

The expression of TRPV1 is increased in MM cell lines and primary MM cells, while TRPV1 inhibition using AMG9810 suppresses MM cell viability

In order to determine the role of TRPV1 in MM, we first evaluated TRPV1 expression in MM cell lines (n = 8) and BM samples from patients with MM (n = 24). Significantly higher levels of TRPV1 transcript were detected in MM BM primary samples and MM cell lines, comparing to normal BM samples (n = 8) (Fig. 1a). To determine the potential of TRPV1 inhibition in myeloma, we exposed a panel of MM cell lines and primary CD138 + MM cells to AMG9810, a specific inhibitor of TRPV1, for 48 h. Treatment with AMG9810 induced potent dose-dependent anti-proliferative effect, with IC50 ranging 2.5–9.5 µM for MM cell lines and 1.5–5 µM for primary MM cells (Fig. 1b). Assessment of apoptotic cell death using Annexin V/PI staining revealed significant increase in early (Annexin V+/PI−) and late (Annexin V+/PI+) apoptosis in MM cells. Importantly, treatment with AMG9810 did not affect cell viability in normal PBMCs (Additional file 1: Fig. 1). Further evaluation of cell death mechanisms triggered by AMG9810 revealed that TRPV1 inhibition using AMG9810 induces fast (1-h exposure) and massive accumulation of intracellular acidic vesicles (detected by acidic vesicle tracer acridine orange) that precedes the subsequent mitochondrial permeabilization (4 and 24 h of treatment) followed by cell death (24 h) (Fig. 1c, d). This was accompanied by elevation of C/EBP homologous protein (CHOP) protein level, indicating that AMG9810 induces profound endoplasmic reticulum (ER) stress. Furthermore, AMG9810 treatment dose-dependently decreased the levels of the anti-apoptotic proteins BCL-2 and MCL-1 and the phosphorylation of mTOR target, pro-survival factor pS6, in MM cells (Fig. 1e). Finally, we observed significant activation of executioner caspase 3 upon AMG9810 treatment (Fig. 1f). Altogether, these results suggest that TRPV1 inhibition with AMG9810 induces profound cytotoxicity in MM cells that is associated with mitochondrial destabilization and can involve both apoptosis and autophagy signaling pathways.

Fig. 1
figure 1

TRPV1 expression and the effect of TRPV1 inhibition on MM cell viability in MM BM samples and MM cell lines. a TRPV1 mRNA levels in bone marrow (BM) samples from healthy donors, MM patients and MM cell lines, measured by quantitative RT-PCR. b Effect of TRPV1 antagonist AMG9810 on viability of MM cell lines and primary CD138+ cells. Cells were incubated with increasing doses of AMG9810 for 48 h, and viability was measured by the XTT method. c–e Time course of the increase in AMG9810-induced vesicle acidification, mitochondrial depolarization and cell death. RPMI8226 and CAG MM cells were exposed to AMG9810 (10 µM) for indicated time points. c Vesicle acidification was measured by flow cytometry using acridine orange (AO) dye. Representative flow cytometry histograms from RPMI8226 cells (left side). Graphs showing percentages of AO-positive RPMI8226 and CAG cells obtained from representative experiment out of three repeats (right side). d Mitochondrial depolarization (ΔΨm loss) in AMG9810-treated cells detected by DiOC6 staining and flow cytometry analysis. Representative flow cytometry histograms from RPMI8226 cells (left side) and graphs showing percentages of MM cells with ΔΨm loss obtained from representative experiment out of three repeats (right side). e AMG9810-induced cell death detected by PI staining. Representative flow cytometry histograms from RPMI8226 cells (left side) and graphs showing the percentages of PI-positive dead RPMI8226 and CAG cells from representative experiment out of three repeats (right side). Data are presented as mean of triplicates ± SD (**p < 0.01). f Western blot analysis of anti-apoptotic proteins BCL-XL and MCL-1, ER stress marker CHOP and mTOR pathway target pS6 in RPMI826 and CAG MM cells before and after treatment with various doses of AMG9810 for 24 h. β-Actin was used as internal control. Representative data from at least two independent experiments are shown. g Caspase 3 activation in response to AMG9810 treatment (5–20 µM, 24-h exposure) was assessed using CaspGLOW Red staining and flow cytometry analysis. Representative histograms (upper panel) and graphs showing percentages of cells with activated Caspase 3 (lower panel). Data are presented as mean of triplicates ± SD (**p < 0.01)

Full size image

TRPV1 inhibition using AMG9810 induces mitochondrial calcium flux and promotes mitochondrial ROS accumulation

Calcium is known to be a key regulator of mitochondrial function and regulates several processes including ATP synthesis and reactive oxygen species (ROS) generation [26]. Therefore, we next evaluated the effect of TRPV1 inhibition on mitochondrial calcium levels. MM cells (RPMI8226, CAG and OPM-1) were for 1 h exposed to AMG9810, labeled with mitochondrial calcium indicator RhoD-2 and analyzed by microscope and flow cytometer. To confirm the mitochondrial localization of RhoD-2 staining, MM cells were co-stained for mitochondrial marker COX IV (Fig. 2a). As demonstrated in Fig. 2a–c, blocking TRPV1 with AMG9810 resulted in an accumulation of mitochondrial calcium. To test whether the increase in RhoD-2 staining upon TRPV1 inhibition is dependent on calcium accumulation, cell-permeable calcium chelator BAPTA-AM was used. Pre-treatment with BAPTA-AM completely abolished the effect of AMG9810 and diminished the AMG9820-induced increase in RhoD-2 staining (Fig. 2a–c).

Fig. 2
figure 2

TRPV1 inhibition using AMG9810 induces increase in mitochondrial calcium levels and mitochondrial ROS levels in MM cells. MM cells were treated with AMG9810 (10 µM), with or without BAPTA-AM (5 µM) for 1 h, and mitochondrial calcium and mitochondrial ROS levels were evaluated. a RPMI8226 cells were labeled with fluorescent calcium indicator Rhod-2 (red fluorescence). To ensure the localization of mitochondria, cells were stained for mitochondrial marker COX IV (green fluorescence). The nucleus was stained with DAPI (blue fluorescence). Representative microscopy images show mitochondrial calcium, × 40 magnification. b, c RPMI8226, CAG and OPM-1 cells were treated with AMG9810 (10 µM), with or without BAPTA-AM (5 µM) for 1 h, stained with Rhod-2 and analyzed by flow cytometry. b Representative plots showing mitochondrial calcium change in response to various treatments, using the mean fluorescent intensity (MFI) of RhoD2 staining in RPMI8226 cells. c Mitochondrial calcium level in RPMI8226, CAG and OPM1 cells is presented as MFI of Rhod-2-stained cells. Data are presented as mean of triplicates ± SD (**p < 0.01). d, e Mitochondrial ROS levels and apoptosis were measured using MitoSOX and Annexin V staining. d Representative images showing MitoSOX/Annexin V staining in RPMI8226 cells (e)

Full size image

Mitochondrial calcium overload has been shown to promote ROS generation in mitochondria [27]. Therefore, the effect of AMG9810 on mitochondrial ROS levels was evaluated. Inhibition of TRPV1 using AMG9810 (1-h exposure) significantly increased mitochondrial ROS, as demonstrated by MitoSOX staining. Consistently, pre-incubation with calcium chelator BAPTA-AM abrogated the increase in mitochondrial ROS induced by AMG9810, suggesting that altered mitochondrial calcium can be the cause rather than a consequence of enhanced oxidative stress observed upon TRPV1 inhibition (Fig. 2d, e). To discriminate apoptotic cells, Annexin V co-staining was utilized. As we determined above, no apoptotic induction was detected following 1-h treatment with AMG9810. Of note, short-term exposure to TRPV1 agonist capsaicin (30 min) had no significant effect on mitochondrial ROS levels, resulting in delayed mild increase in mitochondrial ROS upon 4-h treatment (Additional file 1: Fig. 3A). Furthermore, prolonged TRPV1 inhibition using AMG9810 significantly increased total cellular calcium levels. In contrast, treatment with capsaicin had no significant effect on intracellular calcium following 24-h incubation (Additional file 1: Fig. 3B). Collectively, these results indicate that TRPV1 can be implicated in the regulation of mitochondrial calcium levels and mitochondrial redox signaling. Furthermore, our data point out the differential effect of TRPV1 antagonist AMG9810 on the mitochondria, suggesting that mitochondrial calcium overload triggered TRPV1 inhibition may result in prolonged uncompensated disequilibrium of intracellular calcium homeostasis and subsequent damage.

TRPV1 inhibition using AMG9810 suppresses CXCR4 expression and activity in MM cells

Calcium signaling is known to be tightly involved in the regulation of cancer cell migration and metastatic spread [28]. Furthermore, the role of TRPV1 channels in regulation of cell migration was previously demonstrated [29]. In MM, the CXCL12/CXCR4 chemokine axis plays a key role in MM cell migration and localization into protective BM niche [30]. Therefore, we assessed the effect of TRPV1 inhibition on CXCR4 expression and CXCR4-mediated signaling in MM cells. Treatment with AMG9810 significantly downregulated cell surface CXCR4 in MM cell lines with native (RPMI8226, OPM-1) and over-expressed CXCR4 (RPMI8226-CXCR4). Primary CD138 + MM cells responded similarly, and CXCR4 decrease in expression was detected in response to AMG9810 exposure (Fig. 3a, b). Furthermore, TRPV1 inhibition with AMG9810 completely abrogated the migratory response of CXCR4-expressing MM cells to CXCL12 chemokine (Fig. 3c). Accordingly, TRPV1 inhibition blocked CXCR4-dependent signaling, suppressing the phosphorylation of Erk1/2 and AKT kinases in response to CXCL12 stimulation in MM cells (Fig. 3d). In contrast, TRPV1 activation using the specific agonist capsaicin mildly upregulated cell surface CXCR4 (Fig. 3e, f) and significantly enhanced the migration of RPMI8226-CXCR4 cells in response to CXCL12 (Fig. 3g). Moreover, modulation of TRPV1 activity affected CXCR4-mediated adhesion of MM cells to the bone marrow stromal cells (BMSC). Thus, TRPV1 blockade using AMG9810 significantly suppressed the adhesion, while TRPV1 activation with capsaicin increased the percentage of adherent MM cells (Fig. 3h). Altogether, these data demonstrate that TRPV1 activity is involved in the regulation of CXCR4 expression and function in MM cells, while TRPV1 inhibition negatively regulates CXCR4 axis in MM.

Fig. 3
figure 3

AMG9810 suppresses CXCR4 expression and activity in MM cells. Effect of AMG9810 treatment (10 µM, 1 h, 37 °C) on cell surface CXCR4 expression in RPMI8226, RPMI8226-CXCR4, OPM-1 and primary CD138 + MM cells, measured by flow cytometry. a Representative histograms demonstrating CXCR4 levels in non-treated and AMG9810-treated cells. b CXCR4 expression level is shown as mean fluorescent intensity (MFI), data are presented as mean of triplicates ± SD (**p < 0.01). c RMI8226-CXCR4 cells were pre-treated with indicated doses of AMG9810 for 30 min, and their migratory response to CXCL12 (200 ng/ml) was measured using the trans-well migration assay. d Effect of pre-treatment with AMG9810 (10 µM for 1 h at 37 °C) on CXCL12-induced (200 ng/ml, 30-min activation) intra-cellular signaling in RPMI8226-CXCR4 and OPM-1 cells. Levels of phosphorylated Erk1/2 and AKT proteins, measured by Western blot, β-actin was used as internal control. Representative data from at least two independent experiments are shown. e, f Effect of capsaicin treatment (10 µM, 1 h, 37 °C) on cell surface CXCR4 expression in RPMI8226, RPMI8226-CXCR4 and OPM-1 cells, measured by flow cytometry. g RMI8226-CXCR4 cells were pre-treated with indicated doses of capsaicin (10 µM) for 30 min, and their migratory response to CXCL12 (200 ng/ml) was measured using the trans-well migration assay. h CFSE-prelabeled RPMI8226 and RPMI8226-CXCR4 cells were pre-treated with AMG9810 (10 µM) or capsaicin (10 µM) for 30 min and then co-incubated with BMSC monolayer during 30 min; non-adherent cells were removed, and adherent CFSE-positive cells were enumerated using flow cytometry and expressed as percent of total input cells. Data are presented as mean of triplicates ± SD (**p < 0.01)

Full size image

TRPV1 inhibitor AMG9810 increases the sensitivity to bortezomib and carfilzomib and overcomes bortezomib resistance in MM cells

Bortezomib is commonly used in the triple first-line drug combinations for newly diagnosed MM patients. The development of bortezomib resistance is associated with major clinical problems during treatment of these patients. Therefore, exploring the mechanisms of resistance and strategies to overcome it is in need. Calcium signaling in cancer appears to have crucial role in cancer progression and drug resistance development, while targeting calcium pathway may represent a strategy for chemosensitization [31]. Here, we explored the effect of combination treatment with AMG9810 and bortezomib on MM cell viability. As depicted in Fig. 4a, combination of AMG9810 with bortezomib synergistically increased MM cells death. Moreover, combining AMG9810 with bortezomib interfered with cell cycle progression, markedly decreasing the proliferation, indicated by the percentage of cells in G2/M + S fractions and promoted apoptosis with DNA fragmentation, detected as increased subG0/G1 fraction (Fig. 4b). These results demonstrate that TRPV1 inhibition using AMG9810 enhances bortezomib-induced cytotoxicity, promoting apoptotic cell death with DNA fragmentation in MM cells.

Fig. 4
figure 4

AMG9810 enhances the response to bortezomib in MM cells. a, b MM cells were exposed to low-dose bortezomib (BTZ) (3 nM) in the absence or presence of AMG9810 (10 µM) for 48 h. a Apoptosis was assessed using Annexin V/PI staining and flow cytometry analysis. Percentage of early (Annexin V+/PI−) and late (Annexin V+/PI+) apoptotic cells is presented as mean of triplicates ± SD (**p < 0.01). b Cell cycle distribution was determined using 7-AAD staining. Percent of proliferating cells (G2/M + S fractions), non-proliferating cells (G0/G1 fraction) and cells with fragmented DNA (sub G0/G1 fraction) are presented as mean of triplicates ± SD (**p < 0.01). c Effect of treatment with bortezomib (4 nM for RPMI8226-EV, 6 nM for RPMI8226-CXCR4), AMG9810 (10 µM) or their combination on the viability of MM cells incubated in the absence or presence of BMSCs, measured by PI-exclusion and flow cytometry analysis. d Effect of AMG9810 on BMSC-induced intra-cellular signaling in RPMI8226-CXCR4. RPMI8226-CXCR4 cells were treated with AMG9810 (10 µM), bortezomib (10 nM) or their combination in the absence or presence of BMSC for 24 h. Levels of phosphorylated AKT and pS6 proteins, measured by Western blot, β-actin were used as internal control. e RPMI8226-CXCR4 and RPMI8226-CXCR4-bortezomib-resistant cells were incubated during 48 h with indicated concentrations of bortezomib or AMG9810. Viability was evaluated using the XTT method. Results represent the average of triplicates ± SD (**p < 0.01). f RPMI8226-CXCR4 and RPMI8226-CXCR4-BortRes cells were exposed to bortezomib (BTZ) (10 nM) and carfilzomib (CFZ) (25 nM) in the absence or presence of AMG9810 (10 µM) for 48 h. Apoptosis was assessed using Annexin V/PI staining and flow cytometry analysis. Percentage of early (Annexin V+ /PI−) and late (Annexin V+/PI+) apoptotic cells is presented as mean of triplicates ± SD (**p < 0.01)

Full size image

Based on the ability of AMG9810 to suppress CXCR4 expression and activation on MM cells and given the role of CXCR4 in contact-dependent drug resistance (CAM-DR) of MM cells, we evaluated the effect of TRPV1 inhibition on stroma-mediated protection. Cells with native (RPMI822-EV) and over-expressed CXCR4 (RPMI8226-CXCR4, previously established in our laboratory [25]) were exposed to bortezomib in the absence or presence of BMSC. The presence of BMSC reduced the sensitivity of MM cells to bortezomib, providing partial protection to low CXCR4 expressing RPMI8226-EV cells and almost fully protecting the cells with high CXCR4. Importantly, addition of AMG9810 effectively reversed this stroma-mediated protection (Fig. 4c). To further elucidate the effect of TRPV1 inhibition on stroma-mediated resistance to bortezomib, we evaluated the activation of pro-survival signaling pathways implicated in CAM-DR. As shown in Fig. 4d, the presence of BMSC significantly increased the phosphorylation of AKT kinase and mTOR target pS6. However, TRPV1 inhibition using AMG9810, alone or in combination with bortezomib, effectively suppressed this stroma-mediated phosphorylation. As mentioned above, in order to explore the mechanisms of acquired resistance to bortezomib treatment, we previously established bortezomib-resistant cells by exposing RPMI8226-CXCR4 cells to gradually increasing concentrations of bortezomib. RPMI8226-CXCR4-BortRes cells displayed a significantly decreased sensitivity to the cytotoxic effect of bortezomib. However, AMG9810 treatment inhibited cell viability irrespective of bortezomib sensitivity, demonstrating a similar dose response in both bortezomib-sensitive and resistant lines, respectively (Fig. 4e). The combination of AMG9810 with bortezomib effectively targeted bortezomib-resistant MM cells and resulted in significantly increased cytotoxicity toward both RPMI8226-CXCR4 and RPMI8226-CXCR4-Bort Res cells. Moreover, TRPV1 inhibition was effective in combination with second-generation proteasome inhibitor carfilzomib, significantly increasing MM cell death (Fig. 4f). Based on these results we conclude that TRPV1 inhibition sensitizes MM to bortezomib and carfilzomib and effectively targets both CXCR4-dependent stroma-mediated as well as acquired resistance.

Combining bortezomib with TRPV1 inhibitor AMG9810 promotes mitochondrial damage and induces lysosomal destabilization and uncompensated ER and oxidative stress in MM cells

To determine the molecular mechanisms responsible for the synergistic cytotoxic effect induced by combined bortezomib/AMG9810 treatment and taking into account central role of mitochondria in apoptosis induction, apoptosis-related molecular pathways were analyzed. First, we observed significant increase in mitochondrial ROS levels and associated apoptosis in bortezomib/AMG9810 MM-treated cells, as determined by MitoSOX/Annexin V-positive fraction (Fig. 5a). These changes were accompanied by profound increase in mitochondrial calcium levels, mainly promoted by TRPV1 inhibition (Fig. 5b). Furthermore, bortezomib/AMG9810 combination significantly decreased mitochondrial membrane potential (ΔΨm), detected by decrease in DiOC6 staining (Fig. 5c). Importantly, combining bortezomib with AMG9810 induced profound lysosomal destabilization, as demonstrated by decrease in the LysoTracker staining (Fig. 5d). These results suggest that the increased cytotoxicity obtained upon combination treatment with bortezomib and AMG9810 may rely on the ability of TRPV1 antagonist to interfere with calcium signaling, inducing mitochondrial calcium flux, rapid increase in mitochondrial ROS production, followed by mitochondrial damage and lysosomal destabilization.

Fig. 5
figure 5

AMG9810 in combination with bortezomib elevates mitochondrial ROS and calcium levels, induces mitochondrial and lysosomal destabilization and promotes ER stress. RPMI8226 and OPM1 cells were exposed to low-dose bortezomib (BTZ) (4 nM) in the absence or presence of AMG9810 (10 µM) for 24 h. a Mitochondrial ROS levels and apoptosis were measured using MitoSOX and Annexin V staining. b Mitochondrial calcium levels were assessed using Rhod-2 staining. c Mitochondrial depolarization (ΔΨm loss) was detected by DiOC6 staining and flow cytometry analysis. d Lysosomal membrane destabilization was assessed using LysoTracker staining. Representative images with RPMI8226 cells are shown in upper panels. Bars showing mean of triplicates ± SD (**p < 0.01) in RPMI8226 and OPM-1 cells are presented in lower panels. e RPMI8226, CAG and OPM-1 cells were treated with bortezomib (5 nM), AMG9810 (10 µM) or their combination for 24 h. RNA was extracted and was subjected to qRT-PCR analysis. CHOP, GADD34 and HO-1 mRNA levels were evaluated, using β2-microglobulin as endogenous control gene. f Western blot analysis of ER stress response chaperons HSP70 and HSP40 in RPMI826, CAG and OPM-1 cells before and after 24-h treatment with bortezomib (5 nM), AMG9810 (10 µM) or their combination. β-Actin was used as internal control. Representative data from at least two independent experiments are shown

Full size image

Excess cellular levels of ROS can be deleterious and trigger oxidative stress, causing oxidative damage to DNA and proteins and subsequent cell death [32]. Recent studies link between oxidative stress and ER stress and demonstrate that increased ROS may enhance the production of misfolded proteins, therefore inducing ER stress [33, 34]. In order to confirm it and to evaluate oxidative stress and ER stress induction in response to bortezomib/AMG9810 treatment, mRNA levels of CHOP and DNA damage-inducible 34 (GADD34) (ER stress response genes) as well as heme oxygenase-1 (HO-1) (oxidative stress response gene) were assessed by qRT-PCR. Accordingly, combined bortezomib/AMG9810 treatment resulted in significantly higher expression of ER stress and oxidative stress markers in comparison with a single agent exposure, reflecting enhanced ER stress in MM cells (Fig. 5e).

Induction of ER stress is one of the major mechanisms of bortezomib-mediated cell death. As a response to ER stress conditions, the unfolded protein response (UPR) signal cascade is activated to counteract the occurring damage. The UPR also induces the expression of heat-shock factor chaperons including HSP70 and HSP40 that play cytoprotective role enabling protein folding and reducing ER stress. Consistently, we detected significant increase in HSP70 and HSP40 protein levels in MM cells upon bortezomib treatment. However, TRPV1 inhibition using AMG9810 markedly decreased HSP70 but not HSP40 induced by bortezomib (Fig. 5f). Together, these data suggest that combining bortezomib with AMG9810 interferes with protective UPR activation, decreasing HSP70 and therefore sensitizing MM cells to bortezomib.

Combining bortezomib with TRPV1 inhibitor AMG9810 modifies ubiquitin signaling pathway in MM cells

To get further insight into the molecular mechanisms of bortezomib/AMG9810 synergism, the whole cell proteome profiles of the RPMI8226 cells treated with bortezomib, AMG9810 or their combination were compared using quantitative proteomic studies. Differentially expressed proteins were identified and quantified by LC–MS/MS mass spectrometry. The selection criteria for deregulation were the same for all the samples: identification based on at least two unique peptides and fold difference > 2.0 or < − 2.0. A total of 3343 non-redundant proteins were identified in both untreated and bortezomib/AMG9810-treated RPMI8226 cells. Proteomic analysis revealed unique molecular signature related to the modification of ubiquitin signaling pathway. Thus, 38 proteins related to the ubiquitylation machinery, including ubiquitin ligases and ubiquitin activating enzymes, were significantly downregulated upon combined bortezomib/AMG9810 treatment (Fig. 6a). In line with these results, AMG9810 abolished bortezomib-induced protein ubiquitination in MM cells (Additional file 1: Figure 4). Similarly, carfilzomib treatment promoted protein ubiquitination and increased HSP70 levels, while combination with AMG9810 effectively abrogated these carfilzomib-mediated effects, suggesting common mechanisms of AMG9810/proteasome inhibitors synergism in MM. Of note, TRPV1 agonist capsaicin had no effect on protein ubiquitination and HSP70 levels (Additional file 1: Fig. 5A), further emphasizing the specific and differential activity of TRPV1 antagonist AMG9810 in MM cells. Importantly, cells with over-expressed CXCR4 (RPMI8226-CXCR4) and bortezomib-resistant cells (RPMI8226-CXCR4-BortRes) displayed elevated levels of protein ubiquitination in comparison with the original cell line RPMI8226, which was further increased upon bortezomib treatment. However, combination with AMG9810 impressively reduced the levels of ubiquitinated proteins in bortezomib-resistant MM cells (Fig. 5b).

Fig. 6
figure 6

Combination of AMG810 with bortezomib suppresses ubiquitin signaling and induces mitophagy in MM cells. a RPMI8226 cells were exposed to bortezomib (5 nM), AMG9810 (10 µM) or their combination for 24 h and subjected to cell proteome analysis. a Heatmap of differentially expressed proteins associated with ubiquitin signaling pathway is presented (p < 0.05). b Western blot analysis of cytosolic and mitochondrial fractions of RPMI8226 cells that were exposed to bortezomib (5 nM), AMG9810 (10 µM) or their combination for 24 h. Blots were probed for poly-ubiquitin, HSP70, AIF, LAMP1, PINK1 and VDAC1. α-Tubulin and COX IV were used as markers for cytosolic and mitochondrial fractions, respectively. c, d Effect of bortezomib (5 nM), AMG9810 (10 µM) or their combination on mitochondrial mass in MM cells. Mitochondrial content was measured using MitoSpy staining and flow cytometry analysis. c Representative histograms showing the decrease in mitochondrial mass staining of RPMI8226 cells. d Graphs showing MitoSpy MFI levels in RPMI8226, CAG and OPM-1 cells presented as mean of triplicates ± SD (**p < 0.01)

Full size image

TRPV1 inhibition abolishes bortezomib-mediated mitochondrial UPR and promotes mitophagy in MM cells

Overload of misfolded proteins induced by proteasome inhibition may occur in mitochondria, initiating mitochondrial UPR (mtUPR) [35]. Indeed, the accumulation of ubiquitin-protein conjugates was detected in both cytosolic and mitochondrial fractions of bortezomib-treated RPMI8226 cells. However, the combination of bortezomib and AMG9810 reduced the levels of ubiquitinated proteins in both cytosol and mitochondria (Fig. 6b). Regulation of protein ubiquitination is known to be calcium dependent [36]. Therefore, TRPV1 inhibition and sustained perturbation in intracellular calcium may affect mitochondrial protein ubiquitination and homeostasis, inducing unresolved mitochondrial stress and increasing the sensitivity of MM cells to bortezomib. Mitochondrial HSP70 (mtHSP70) has been proposed as a potential marker for mtUPR, being indispensable for mitochondrial function, suppressing ROS-induced mitochondrial damage and permeabilization and protecting against cell death [37]. The latter was illustrated by an increase in mtHSP70 chaperon’s expression upon exposure to bortezomib. Importantly, AMG9810 treatment completely depleted bortezomib-induced HSP70 in the mitochondria. This was accompanied by release of mitochondrial pro-apoptotic proteins AIF to the cytosol, indicating extensive mitochondrial damage (Fig. 6b). Furthermore, lysosome-associated membrane protein 1 (LAMP1) levels in the mitochondrial fraction was increased upon AMG9810 treatment, suggesting lysosomal–mitochondrial interactions. Finally, we found that mitochondrial PTEN-induced putative kinase 1 (PINK1) levels were increased upon to exposure to AMG9810 alone or in combination with bortezomib. PINK1 stabilization on the outer membrane of impaired mitochondria is known to promote the selective lysosome-mediated clearance of defective mitochondria by mitophagy process [38]. In addition, the degradation of outer mitochondrial membrane protein VDAC was observed upon combined AMG9810/bortezomib treatment, further supporting the notion that TRPV1 inhibition in combination with bortezomib induces non-reversible mitochondrial damage and mitophagy (Fig. 6b). In line with the above, we detected significant decrease in mitochondrial mass in MM cells exposed to AMG9810/bortezomib treatment (Fig. 6c, d).

Inhibition of ubiquitin pathway is essential for AMG9810-mediated effects in MM cells

To estimate the role of the ubiquitin pathway in AMG9810-mediated anti-MM effects, we utilized MLN4924 (pevonedistat), inhibitor of NEDD8 activating enzyme that suppresses Cullin-E3 ligase activity [39]. Among other ubiquitin-related proteins, we detected reduced NEDD8 levels in RPMI8226 cells upon bortezomib/AMG9810 exposure. Notably, combining MLN4924 with bortezomib significantly increased cell death in MM cells (Additional file 1: Figure 6A). Furthermore, NED88 inhibition using MLN4924 abolished bortezomib-induced ubiquitination and suppressed bortezomib-mediated protective mtUPR, as demonstrated by decrease in bortezomib-induced mtHSP70 levels (Additional file 1: Fig. 6B). Finally, NEDD8 inhibition in combination with bortezomib synergistically induced mitochondrial oxidative damage with subsequent MM cell death (Additional file 1: Fig. 6C, D). These results suggest that ubiquitin pathway and mitochondrial activity are critical targets of TRPV1 antagonist in MM cells.

The combination of AMG9810 with bortezomib effectively targets MM cells in vivo in the BM niche

Lastly, we extended our in vitro findings and investigated the effectiveness of a combination approach consisting of AM9810 and bortezomib in vivo, using our xenograft model of MM with BM involvement. In this model intravenous injection of CXCR4-over-expressing myeloma cells into NSG mice results in preferential BM homing and development of a lethal disease resembling human MM [25]. Subsequently, NSG mice were inoculated with RPMI8226-CXCR4 cells and were treated with bortezomib (0.5 mg/kg), AMG9810 (10 mg/kg) or their combination for three weeks, total of 6 injections (Fig. 7a). As demonstrated in Fig. 7b, c, single agent AMG9810 treatment demonstrated marked anti-myeloma activity. Furthermore, the combination of both agents significantly reduced MM tumor load in the BM. Altogether, these results demonstrate the cooperative anti-myeloma activity of AMG9810 and bortezomib in vivo, enabling effective targeting of MM even in the protective BM microenvironment.

Fig. 7
figure 7

Combination of AMG9810 with bortezomib effectively targets MM tumor burden in vivo in the BM niche. a RPMI8226-CXCR4 (5 × 106) were intravenously (i.v.) injected into NSG mice and three days later were treated with subcutaneous bortezomib injections (0.5 mg/kg) twice a week, total of 6 injections, intraperitoneal AMG9810 injections (10 mg/kg) twice a week, total of 6 injections or the combination of both agents. On day 24 following MM cell inoculation, mice were killed and the human MM burden in the murine BM was evaluated. b, c Response of tumor burden, presented as percent of RPMI8226-CXCR4 MM cells in the BM, five mice per group. Data are presented as mean ± SE, **p < 0.01

Full size image

Discussion

Despite the recent advances and improving the clinical outcomes of patients with myeloma, anti-MM treatment remains challenging and novel treatment strategies are urgently needed. Drug resistance remains a major challenge for MM cure.

Calcium is a critical secondary messenger that mediates various cellular processes in normal and cancer cells, keeping the balance between proliferation, differentiation and cell death [40,41,42]. Calcium is also one of the critical regulators of cell migration of various cell types, including tumor cells [40]. Furthermore, calcium signaling was proposed to play a role in drug resistance of cancer cells [43]. TRPV1 has been recognized as an important regulator of intracellular calcium levels and was shown to be functionally expressed in various cancer cells. These findings prompted us to consider the TRPV1 pathway as a therapeutic target in MM.

Our data highlight the novel role of TRPV1-dependent signaling in MM cell growth and drug sensitivity. TRPV1 inhibition using pharmacological inhibitor AMG9810 resulted in calcium-dependent accumulation of mitochondrial ROS, followed by mitochondrial destabilization and MM cell death. These results are in accordance with previous findings showing that calcium acts as a key regulator of mitochondrial function and that its overload can impair electron transport leading to ROS generation [26]. Furthermore, changes in mitochondrial calcium have been shown to regulate many cellular processes such as apoptosis [44], autophagy [45] and organelle crosstalk between mitochondria and ER [46]. Excessive calcium in the mitochondria is known to be associated with sustained activation of mitochondrial membrane permeability and the release of apoptotic factors such as cytochrome c into the cytosol [47]. Indeed, sustained activation of both apoptotic and autophagy pathways was observed upon TRPV1 inhibition in MM cells, including depletion of pro-apoptotic BCL-2 and MCL-1, increase in activated caspase 3 levels and increase in Annexin V staining. Additionally, increase in vesicle acidification and suppression of mTOR pathway suggested the activation of autophagy signaling following AMG9810 treatment. Furthermore, AMG9810-induced increase in CHOP indicated profound ER and mitochondrial stress mediated by TRPV1 inhibition.

Another important effect observed upon AMG9810 exposure was significant decrease in CXCR4 expression and function in MM cells, resulting in suppression of CXCL12-mediated signaling, while activation of TRPV1 using capsaicin enhanced CXCR4-mediated migration and adhesion. CXCR4/CXCL12 chemokine axis was shown to play pro-tumorigenic role in MM development and progression, inducing MM cell localization in the BM niche and promoting environment-mediated drug resistance [48]. CXCR4 activity is known to be dependent on calcium flux [49]. In normal and cancer cells, CXCL12 activation induces release of calcium from internal stores, triggering phospholipase C activation and the generation of inositol trisphosphate and diacylglycerol. Thus, calcium signaling is associated with processes that occur during metastasis, including cell migration and invasion [50]. Indeed, previous work demonstrated that increased extracellular calcium levels and intracellular calcium flux upregulated CXCR4 expression and activity in CD34+ hematopoietic stem cells [51]. In agreement with these findings, here we show that TRPV1 inhibition interferes with calcium signaling and suppresses both CXCR4 expression and activity in MM cells. On the contrary, TRPV1 activation using capsaicin promotes calcium influx, resulting in transient increase in cytosol calcium levels and, therefore, supporting CXCR4-mediated activity. Hence, our data demonstrate that TRPV1 is functionally connected to CXCR4-mediated activation, migration and adhesion of MM cells and reveal TRPV1 as a potential novel target in MM, possibly implicated in disease progression and refractoriness. Accordingly, inhibition of TRPV1 using AMG9810 effectively overcame stroma-mediated protection and restored the sensitivity of MM cells to bortezomib.

Moreover, combination of bortezomib with AMG9810 revealed synergistic anti-myeloma activity with unique mechanism. Simultaneous inhibition of proteasome and TRPV1 in MM cells promoted extensive mitochondrial damage with deleteriously increased mitochondrial ROS, induced lysosomal destabilization and uncompensated ER stress.

The major mechanism of bortezomib-induced cell death involves the accumulation of misfolded protein aggregates, which induce ER stress followed by an UPR. Activation of UPR may induce several lines of responses, acting to promote cellular survival or committing the cell to apoptosis. Increased expression of chaperons restores the folding capacity and ameliorate the stress, therefore reducing the responsiveness to bortezomib. Indeed, HSP70 induction is known to be a part of compensatory UPR in MM, while HSP70 inhibition was shown to be effective in combination with bortezomib [52]. Furthermore, the increased levels of chaperones including HSP70 have been associated with resistance to proteasome inhibitors in MM cells [53]. Our data show that TRPV1 inhibition using AMG9810 effectively downregulates HSP70 levels, overcoming the compensatory response induced by proteasome inhibitors bortezomib and carfilzomib. This may provide mechanistical hint, explaining the observed synergism between proteasome inhibitors and AMG9810 in MM cells. Noteworthy, the regulatory link between TRPV1 and HSP70 in epithelial cells was previously reported [54].

Notably, in addition to cytosolic HSP70, profound increase in mitochondrial HSP70 levels was detected upon bortezomib exposure, suggesting the induction of mitochondrial UPR. The mtHSP70 machinery plays a critical role in maintaining proteostasis balance in the mitochondria and is induced upon proteotoxic stress [55]. It was shown that elevated mtHSP70 prevents mitochondrial membrane depolarization and protects the cells from apoptosis by obliterating conformational changes in BAX and activating the AKT pathway [56]. Overexpression of mtHSP70 in cancer cells causes resistance against chemotherapeutic drugs like cisplatin [57], while reduction in mtHSP70 leads to increased apoptosis by decreasing mitochondrial membrane potential [58]. However, the role of mtUPR in responses to proteasome inhibitor therapy remains mainly unexplored. Thus, our work provides the evidence for mtHSP70 increase and mtUPR induction upon bortezomib treatment and suggests its involvement in cell protection and drug resistance. Importantly, AMG9810 completely depleted bortezomib-induced mtHSP70 and therefore abrogated protective mtUPR.

Another important finding of our study indicates that bortezomib-induced mtUPR involves the accumulation of ubiquitin-protein conjugates in mitochondrial fraction following bortezomib exposure. Inhibition of the degradation of ubiquitin-labeled proteins is known consequence of proteasome inhibitors. Of note, AMG9810 in combination with bortezomib significantly downregulated the levels of proteins related to ubiquitination system, including ubiquitin ligases and ubiquitin activating enzymes. Accordingly, TRPV1 inhibition with AMG9810 significantly diminished the accumulation of poly-ubiquitinated proteins in both the cytosol and the mitochondria. Inhibition of the ubiquitination system was shown to be effective in combination with proteasome inhibitors. For example, lenalidomide, an inhibitor of E3 ubiquitin ligase cereblon, is potent anti-MM drug [59]. Furthermore, ubiquitin-activating enzyme inhibition using TAK-243 molecule demonstrated anti-MM activity in preclinical models [60]. Recent evidences show a regulatory role for calcium in modulating ubiquitination system. Thus, ubiquitination activity of numerous E3 ligases is regulated by calcium [36]. Thereby, inhibition of ubiquitination by AMG9810 and potentiation of ER and mitochondrial stress by bortezomib can represent a mechanism that contribute to bortezomib/AMG9810 synergism. Furthermore, our data revealed increased basal level of protein ubiquitination in bortezomib-resistant cells, while AMG9810 in combination with bortezomib reduced the accumulation of ubiquitinated proteins in resistant cells. Therefore, modulation of the ubiquitination activity using TRPV1 inhibitor AMG9810 could be a new approach to target bortezomib-resistant MM cells.

Moreover, calcium is an important molecule of crosstalk at the ER-mitochondria junctions [46]. Accordingly, it was shown that E3 ligase Mahogunin Ring Finger 1(MGRN1) regulates in a calcium-dependent manner the exchanges between the ER and mitochondria and influences mitochondrial quality control through mitophagy [61]. Therefore, we hypothesize that TRPV1 inhibition results in sustained perturbation in intracellular calcium, interferes with ubiquitination activity and in combination with bortezomib promotes unresolved mitochondrial damage, inducing mitophagy in MM cells. This suggestion was further supported by our findings demonstrating the decrease in mitochondrial mass, mitochondrial-lysosomal fusion and mitochondrial accumulation of PINK1, a master regulator of UPR-induced mitophagy.

Finally, the effect of AMG9810 was validated in our in vivo model of CXCR4-driven human MM engrafting in murine BM. Our results demonstrate that single-agent treatment with AMG9810 targeted MM cells in the BM niche and significantly reduced tumor load. Most importantly, the combination of AMG9810 with bortezomib demonstrated preferential anti-MM activity, effectively reducing MM tumor load.

Conclusions

Altogether, our data indicate that TRPV1 is implicated in MM cell survival, proliferation, migration, microenvironment interactions and stress response. TRPV1 inhibition by AMG9810 impairs calcium homeostasis, inhibits CXCR4-mediated migration and stromal protection, synergizes with bortezomib, targets ubiquitin pathway and cytoprotective mtUPR, impairs mitochondria, destabilizes lysosome and promotes MM cell death. These results unravel the mechanism mediating the strong synergistic anti-MM activity of bortezomib in combination with TRPV1 inhibition which may be translated into the clinic.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its Additional file 1 files.

Abbreviations

AIF:

Apoptosis-inducing factor

AO:

Acridine orange

ATCC:

American Type Culture Collection

BCL-2:

B-cell lymphoma 2

BCL-XL:

B-cell lymphoma extra large

BM:

Bone marrow

BMSC:

Bone marrow stromal cells

CFSE:

Carboxyfluorescein succinimidyl ester

CHOP:

C/EBP homologous protein

COX IV:

Cytochrome c oxidase IV

CXCL12:

C-X-C Motif Chemokine Ligand 12

CXCR4:

C-X-C Motif Chemokine Receptor 4

DNA:

Deoxyribonucleic acid

ECL:

Enhanced luminol-based chemiluminescent

ELISA:

Enzyme-bound immunosorbent analysis

ER:

Endoplasmic reticulum

Erk 1/2:

Extracellular signal-regulated protein kinase 1/2

FACS:

Fluorescence-activated cell sorting

FCS:

Fetal calf serum

FITC:

Fluorescein isothiocyanate

GFP:

Green fluorescent protein

HO-1:

Heme oxygenase 1

HSP40:

Heat-shock protein 40

HSP70:

Heat-shock protein 70

qRT-PCR:

Quantitative reverse transcription polymerase chain reaction

LAMP1:

Lysosomal-associated membrane protein 1

MCL-1:

Myeloid cell leukemia 1

MM:

Multiple myeloma

mTOR:

Mammalian target of rapamycin

PI:

Propidium iodide

PINK1:

PTEN-Induced Kinase 1

PVDF:

Polyvinylidene fluoride

SDS-PAGE:

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis

RNA:

Ribonucleic acid

ROS:

Reactive oxygen species

UPR:

Unfolded protein response

VDAC:

Voltage-dependent anion channel

References

  1. Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:17046.

    Article  PubMed  Google Scholar 

  2. Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385(9983):2197–208.

    Article  PubMed  CAS  Google Scholar 

  3. Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543–56.

    Article  CAS  PubMed  Google Scholar 

  4. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):52–61.

    Article  Google Scholar 

  5. Rajkumar SV. Myeloma today: disease definitions and treatment advances. Am J Hematol. 2016;91(1):90–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Nilius B, Owsianik G. The transient receptor potential family of ion channels. Genome Biol. 2011;12(3):218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816–24.

    Article  CAS  PubMed  Google Scholar 

  8. Ferrer-Montiel A, Fernandez-Carvajal A, Planells-Cases R, Fernandez-Ballester G, Gonzalez-Ros JM, Messeguer A, et al. Advances in modulating thermosensory TRP channels. Expert Opin Ther Pat. 2012;22(9):999–1017.

    Article  CAS  PubMed  Google Scholar 

  9. Aneiros E, Cao L, Papakosta M, Stevens EB, Phillips S, Grimm C. The biophysical and molecular basis of TRPV1 proton gating. EMBO J. 2011;30(6):994–1002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ramirez-Barrantes R, Cordova C, Gatica S, Rodriguez B, Lozano C, Marchant I, et al. Transient receptor potential vanilloid 1 expression mediates capsaicin-induced cell death. Front Physiol. 2018;9:682.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bujak JK, Kosmala D, Szopa IM, Majchrzak K, Bednarczyk P. Inflammation, cancer and immunity-implication of TRPV1 channel. Front Oncol. 2019;9:1087.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Han SB, Kim H, Cho SH, Lee JD, Chung JH, Kim HS. Transient receptor potential vanilloid-1 in epidermal keratinocytes may contribute to acute pain in herpes zoster. Acta Derm Venereol. 2016;96(3):319–22.

    Article  CAS  PubMed  Google Scholar 

  13. Yu X, Yu M, Liu Y, Yu S. TRP channel functions in the gastrointestinal tract. Semin Immunopathol. 2016;38(3):385–96.

    Article  CAS  PubMed  Google Scholar 

  14. Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci. 2002;5(9):856–60.

    Article  CAS  PubMed  Google Scholar 

  15. Diaz-Garcia CM, Morales-Lazaro SL, Sanchez-Soto C, Velasco M, Rosenbaum T, Hiriart M. Role for the TRPV1 channel in insulin secretion from pancreatic beta cells. J Membr Biol. 2014;247(6):479–91.

    Article  CAS  PubMed  Google Scholar 

  16. Rehman R, Bhat YA, Panda L, Mabalirajan U. TRPV1 inhibition attenuates IL-13 mediated asthma features in mice by reducing airway epithelial injury. Int Immunopharmacol. 2013;15(3):597–605.

    Article  CAS  PubMed  Google Scholar 

  17. Bertin S, Aoki-Nonaka Y, de Jong PR, Nohara LL, Xu H, Stanwood SR, et al. The ion channel TRPV1 regulates the activation and proinflammatory properties of CD4(+) T cells. Nat Immunol. 2014;15(11):1055–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lozano C, Cordova C, Marchant I, Zuniga R, Ochova P, Ramirez-Barrantes R, et al. Intracellular aggregated TRPV1 is associated with lower survival in breast cancer patients. Breast Cancer (Dove Med Press). 2018;10:161–8.

    CAS  Google Scholar 

  19. Gkika D, Prevarskaya N. Molecular mechanisms of TRP regulation in tumor growth and metastasis. Biochim Biophys Acta. 2009;1793(6):953–8.

    Article  CAS  PubMed  Google Scholar 

  20. Sanchez MG, Sanchez AM, Collado B, Malagarie-Cazenave S, Olea N, Carmena MJ, et al. Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur J Pharmacol. 2005;515(1–3):20–7.

    Article  CAS  PubMed  Google Scholar 

  21. Amantini C, Ballarini P, Caprodossi S, Nabissi M, Morelli MB, Lucciarini R, et al. Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis. 2009;30(8):1320–9.

    Article  CAS  PubMed  Google Scholar 

  22. Amantini C, Mosca M, Nabissi M, Lucciarini R, Caprodossi S, Arcella A, et al. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J Neurochem. 2007;102(3):977–90.

    Article  CAS  PubMed  Google Scholar 

  23. Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood. 2000;96(7):2528–36.

    Article  CAS  PubMed  Google Scholar 

  24. Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget. 2014;5(22):11283–96.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Beider K, Rosenberg E, Bitner H, Shimoni A, Leiba M, Koren-Michowitz M, et al. The sphingosine-1-phosphate modulator FTY720 targets multiple myeloma via the CXCR4/CXCL12 pathway. Clin Cancer Res. 2017;23(7):1733–47.

    Article  CAS  PubMed  Google Scholar 

  26. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol. 2004;287(4):C817–33.

    Article  CAS  PubMed  Google Scholar 

  27. Delierneux C, Kouba S, Shanmughapriya S, Potier-Cartereau M, Trebak M, Hempel N. Mitochondrial calcium regulation of redox signaling in cancer. Cells. 2020;9(2):432.

    Article  CAS  PubMed Central  Google Scholar 

  28. Xu M, Seas A, Kiyani M, Ji KSY, Bell HN. A temporal examination of calcium signaling in cancer-from tumorigenesis, to immune evasion, and metastasis. Cell Biosci. 2018;8:25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Waning J, Vriens J, Owsianik G, Stuwe L, Mally S, Fabian A, et al. A novel function of capsaicin-sensitive TRPV1 channels: involvement in cell migration. Cell Calcium. 2007;42(1):17–25.

    Article  CAS  PubMed  Google Scholar 

  30. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kischel P, Girault A, Rodat-Despoix L, Chamlali M, Radoslavova S, Abou Daya H, et al. Ion channels: new actors playing in chemotherapeutic resistance. Cancers (Basel). 2019;11(3):376.

    Article  CAS  Google Scholar 

  32. Kardeh S, Ashkani-Esfahani S, Alizadeh AM. Paradoxical action of reactive oxygen species in creation and therapy of cancer. Eur J Pharmacol. 2014;735:150–68.

    Article  CAS  PubMed  Google Scholar 

  33. Wang J, Yang X, Zhang J. Bridges between mitochondrial oxidative stress, ER stress and mTOR signaling in pancreatic beta cells. Cell Signal. 2016;28(8):1099–104.

    Article  CAS  PubMed  Google Scholar 

  34. Dandekar A, Mendez R, Zhang K. Cross talk between ER stress, oxidative stress, and inflammation in health and disease. Methods Mol Biol. 2015;1292:205–14.

    Article  CAS  PubMed  Google Scholar 

  35. Qureshi MA, Haynes CM, Pellegrino MW. The mitochondrial unfolded protein response: Signaling from the powerhouse. J Biol Chem. 2017;292(33):13500–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Mukherjee R, Das A, Chakrabarti S, Chakrabarti O. Calcium dependent regulation of protein ubiquitination—interplay between E3 ligases and calcium binding proteins. Biochim Biophys Acta Mol Cell Res. 2017;1864(7):1227–35.

    Article  CAS  PubMed  Google Scholar 

  37. Pellegrino MW, Nargund AM, Haynes CM. Signaling the mitochondrial unfolded protein response. Biochim Biophys Acta. 2013;1833(2):410–6.

    Article  CAS  PubMed  Google Scholar 

  38. Nguyen TN, Padman BS, Lazarou M. Deciphering the molecular signals of PINK1/parkin mitophagy. Trends Cell Biol. 2016;26(10):733–44.

    Article  CAS  PubMed  Google Scholar 

  39. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458(7239):732–6.

    Article  CAS  PubMed  Google Scholar 

  40. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4(7):517–29.

    Article  CAS  PubMed  Google Scholar 

  41. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem. 2012;287(38):31666–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Chen YF, Chen YT, Chiu WT, Shen MR. Remodeling of calcium signaling in tumor progression. J Biomed Sci. 2013;20:23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Busselberg D, Florea AM. Targeting intracellular calcium signaling ([Ca(2+)]i) to overcome acquired multidrug resistance of cancer cells: a mini-overview. Cancers (Basel). 2017;9(5):48.

    Article  CAS  Google Scholar 

  44. Jacobson J, Duchen MR. Mitochondrial oxidative stress and cell death in astrocytes–requirement for stored Ca2+ and sustained opening of the permeability transition pore. J Cell Sci. 2002;115(Pt 6):1175–88.

    CAS  PubMed  Google Scholar 

  45. Hoyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell. 2007;25(2):193–205.

    Article  PubMed  CAS  Google Scholar 

  46. Filadi R, Theurey P, Pizzo P. The endoplasmic reticulum-mitochondria coupling in health and disease: molecules, functions and significance. Cell Calcium. 2017;62:1–15.

    Article  CAS  PubMed  Google Scholar 

  47. Rasola A, Bernardi P. Mitochondrial permeability transition in Ca(2+)-dependent apoptosis and necrosis. Cell Calcium. 2011;50(3):222–33.

    Article  CAS  PubMed  Google Scholar 

  48. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113(18):4341–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Princen K, Hatse S, Vermeire K, De Clercq E, Schols D. Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry. Cytometry A. 2003;51(1):35–45.

    Article  PubMed  CAS  Google Scholar 

  50. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927–31.

    Article  CAS  PubMed  Google Scholar 

  51. Wu Q, Shao H, Darwin ED, Li J, Li J, Yang B, et al. Extracellular calcium increases CXCR4 expression on bone marrow-derived cells and enhances pro-angiogenesis therapy. J Cell Mol Med. 2009;13(9B):3764–73.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Eugenio AIP, Fook-Alves VL, de Oliveira MB, Fernando RC, Zanatta DB, Strauss BE, et al. Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma. Oncotarget. 2017;8(70):114698–709.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Nikesitch N, Ling SC. Molecular mechanisms in multiple myeloma drug resistance. J Clin Pathol. 2016;69(2):97–101.

    Article  CAS  PubMed  Google Scholar 

  54. Bromberg Z, Goloubinoff P, Saidi Y, Weiss YG. The membrane-associated transient receptor potential vanilloid channel is the central heat shock receptor controlling the cellular heat shock response in epithelial cells. PLoS ONE. 2013;8(2):e57149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Srivastava S, Vishwanathan V, Birje A, Sinha D, D’Silva P. Evolving paradigms on the interplay of mitochondrial Hsp70 chaperone system in cell survival and senescence. Crit Rev Biochem Mol Biol. 2019;54(6):517–36.

    Article  CAS  PubMed  Google Scholar 

  56. Yang L, Guo W, Zhang Q, Li H, Liu X, Yang Y, et al. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions. J Mol Biol. 2011;414(5):654–66.

    Article  CAS  PubMed  Google Scholar 

  57. Yang L, Li H, Jiang Y, Zuo J, Liu W. Inhibition of mortalin expression reverses cisplatin resistance and attenuates growth of ovarian cancer cells. Cancer Lett. 2013;336(1):213–21.

    Article  CAS  PubMed  Google Scholar 

  58. Na Y, Kaul SC, Ryu J, Lee JS, Ahn HM, Kaul Z, et al. Stress chaperone mortalin contributes to epithelial-mesenchymal transition and cancer metastasis. Can Res. 2016;76(9):2754–65.

    Article  CAS  Google Scholar 

  59. Kortum KM, Zhu YX, Shi CX, Jedlowski P, Stewart AK. Cereblon binding molecules in multiple myeloma. Blood Rev. 2015;29(5):329–34.

    Article  CAS  PubMed  Google Scholar 

  60. Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, et al. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood. 2019;133(14):1572–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Mukherjee R, Chakrabarti O. Regulation of Mitofusin1 by Mahogunin Ring Finger-1 and the proteasome modulates mitochondrial fusion. Biochim Biophys Acta. 2016;1863(12):3065–83.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Devorah Olam (Institute of Gene Therapy, Hebrew University Hospital) for technical assistance.

Funding

We wish to thank the Naor family for a generous research grant memorizing their dear son in law Mr. Guy Weinshtock "The Guy Weinshtock Multiple Myeloma Foundation," in support of research in the field of MM at the Division of Hematology at Chaim Sheba Medical Center, Tel Hashomer.

Author information

Authors and Affiliations

  1. Division of Hematology, CBB and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel

    Katia Beider, Evgenia Rosenberg, Valeria Dimenshtein-Voevoda, Yaarit Sirovsky, Julia Vladimirsky, Hila Magen, Olga Ostrovsky, Avichai Shimoni & Arnon Nagler

  2. Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel

    Zohar Bromberg, Lola Weiss & Amnon Peled

Authors
  1. Katia Beider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evgenia Rosenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valeria Dimenshtein-Voevoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yaarit Sirovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Julia Vladimirsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hila Magen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Olga Ostrovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Avichai Shimoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zohar Bromberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lola Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Amnon Peled
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Arnon Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

K.B., A.P. and A.N. conceived and designed the experiments; K.B., E.R., V. D.-V., J. V., Y.S. and L.W. performed the experiments; K.B., O.O. and A.N. analyzed the data; Z. B., H.M., A.S. and A.N. contributed with reagents and patient material; and K.B., A.P. and A.N. wrote the paper. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Arnon Nagler.

Ethics declarations

Ethics approval and consent to participate

The study was approved by Institutional Review Board of the Sheba Medical Center. Animal experiments were approved by the Animal Care Committee of the Hebrew University, Jerusalem.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing financial interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1

. Supplementary Methods and Results.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beider, K., Rosenberg, E., Dimenshtein-Voevoda, V. et al. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. J Hematol Oncol 13, 158 (2020). https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-020-00993-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-020-00993-0

Keywords

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us